青蒿
青蒿素
转基因
转基因作物
生物
农杆菌
生物化学
基因
恶性疟原虫
免疫学
疟疾
作者
Jianlin Chen,Huaming Fang,Yun-Peng Ji,Gaobin Pu,Yanwu Guo,Lili Huang,Zhigao Du,Benye Liu,Hechun Ye,Guofeng Li,Hong Wang
出处
期刊:Planta Medica
[Thieme Medical Publishers (Germany)]
日期:2011-04-20
卷期号:77 (15): 1759-1765
被引量:72
标识
DOI:10.1055/s-0030-1271038
摘要
Artemisinin is an effective antimalarial drug isolated from the medicinal plant Artemisia annua L. Due to its increasing market demand and the low yield in A. annua, there is a great interest in increasing its production. In this paper, in an attempt to increase artemisinin content of A. ANNUA by suppressing the expression of β-caryophyllene synthase, a sesquiterpene synthase competing as a precursor of artemisinin, the antisense fragment (750 bp) of β-caryophyllene synthase cDNA was inserted into the plant expression vector pBI121 and introduced into A. annua by Agrobacterium-mediated transformation. PCR and Southern hybridization confirmed the stable integration of multiple copies of the transgene in 5 different transgenic lines of A. annua. Reverse transcription PCR showed that the expression of endogenous CPS in the transgenic lines was significantly lower than that in the wild-type control A. annua plants, and β-caryophyllene content decreased sharply in the transgenic lines in comparison to the control. The artemisinin content of one of the transgenic lines showed an increase of 54.9 % compared with the wild-type control. The present study demonstrated that the inhibition pathway in the precursor competition for artemisinin biosynthesis by anti-sense technology is an effective means of increasing the artemisinin content of A. annua plants.
科研通智能强力驱动
Strongly Powered by AbleSci AI